If I Were A Valeant Pharmaceuticals Shareholder, This Would Infuriate Me

Image source: Getty Images.Drugmaker Valeant Pharmaceuticals (NYSE: VRX) has had a really rough go of things over the past year. Since peaking at approximately $264 a share last summer, shares of the once nearly megacap company have fallen back into mid-cap status.At the heart of Valeant's issues are its pricing practices under the leadership of now-former CEO J.

BING NEWS:
  • US economic growth slows; Anglo American shares surge after BHP proposes £31.1bn takeover – as it happened
    FTSE 100 hits another record, after buyout offer for Anglo American, while US economy slowed by more than expected in the last quarter ...
    04/25/2024 - 3:43 am | View Link
  • Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
    Basel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis continued our strong momentum with both sales growth and core margin expansion in Q1. Our ...
    04/22/2024 - 6:00 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News